Korsana reports Q3 2026 results, advances KRSA-028 toward the clinic
The company said it expects Phase 1 healthy volunteer data for its lead Alzheimer's candidate in mid-2027, with proof-of-concept patient data by year-end 2027 or early 2028.
SEC filing